OBJECTIVES: Although cervical cancer is an AIDS-defining illness, few HIV-infected women are routinely screened for cervical cancer in Thailand. We screened HIV-infected women for cervical cancer as a component of HIV care and assessed high-risk human papillomavirus (HPV) and cervical cancer prevalence. METHODS: From July 2003 through February 2004, HIV-infected women attending either an infectious disease clinic or a sexually transmitted infection (STI) clinic in Bangkok were tested for high-risk HPV types by Hybrid Capture 2 and screened for cervical cancer by Pap test; those with abnormal cervical cytology were referred for diagnosis and treatment. RESULTS: Two hundred ten HIV-infected women at an infectious disease clinic (n = 150) and an STI clinic (n = 60) received cervical cancer screening. The high-risk HPV prevalence was 38.6% and the prevalence of abnormal cervical cytology was 20.4%. Abnormal cervical cytology and high-risk HPV detection were associated (P < 0.001). We received pathology reports for 23 (53.5%) of 43 women, including all those with a Pap test showing high-grade squamous intraepithelial lesions; the cervical cancer prevalence was 1.9% (4 of 210; 95% confidence interval, 0.5-4.8%). CONCLUSION: The estimated prevalence of high-risk HPV and cervical cancer among HIV-infected women in Thailand was high. This emphasizes the need to integrate cervical cancer screening into HIV care.
OBJECTIVES: Although cervical cancer is an AIDS-defining illness, few HIV-infectedwomen are routinely screened for cervical cancer in Thailand. We screened HIV-infectedwomen for cervical cancer as a component of HIV care and assessed high-risk human papillomavirus (HPV) and cervical cancer prevalence. METHODS: From July 2003 through February 2004, HIV-infectedwomen attending either an infectious disease clinic or a sexually transmitted infection (STI) clinic in Bangkok were tested for high-risk HPV types by Hybrid Capture 2 and screened for cervical cancer by Pap test; those with abnormal cervical cytology were referred for diagnosis and treatment. RESULTS: Two hundred ten HIV-infectedwomen at an infectious disease clinic (n = 150) and an STI clinic (n = 60) received cervical cancer screening. The high-risk HPV prevalence was 38.6% and the prevalence of abnormal cervical cytology was 20.4%. Abnormal cervical cytology and high-risk HPV detection were associated (P < 0.001). We received pathology reports for 23 (53.5%) of 43 women, including all those with a Pap test showing high-grade squamous intraepithelial lesions; the cervical cancer prevalence was 1.9% (4 of 210; 95% confidence interval, 0.5-4.8%). CONCLUSION: The estimated prevalence of high-risk HPV and cervical cancer among HIV-infectedwomen in Thailand was high. This emphasizes the need to integrate cervical cancer screening into HIV care.
Authors: James L Klosky; Heather L Gamble; Sheri L Spunt; Mary E Randolph; Daniel M Green; Melissa M Hudson Journal: Cancer Date: 2009-12-15 Impact factor: 6.860
Authors: Cynthia Firnhaber; Khumbuzile Zungu; Simon Levin; Pam Michelow; Luis J Montaner; Patrick McPhail; Anna-Lise Williamson; Bruce R Allan; Charlie Van der Horst; Allen Rinas; Ian Sanne Journal: Acta Cytol Date: 2009 Jan-Feb Impact factor: 2.319
Authors: Louise Sigfrid; Georgina Murphy; Victoria Haldane; Fiona Leh Hoon Chuah; Suan Ee Ong; Francisco Cervero-Liceras; Nicola Watt; Alconada Alvaro; Laura Otero-Garcia; Dina Balabanova; Sue Hogarth; Will Maimaris; Kent Buse; Martin Mckee; Peter Piot; Pablo Perel; Helena Legido-Quigley Journal: PLoS One Date: 2017-07-21 Impact factor: 3.240
Authors: Chandrika J Piyathilake; Suguna Badiga; Greer A Burkholder; Shuko Harada; James L Raper Journal: Cancer Med Date: 2021-02-19 Impact factor: 4.452